Nordea Markets
-
Finnish telecoms company DNA braved choppy conditions this week with a new €250m seven year bond to fund its tender offer for bonds due in 2018 and 2021 following a roadshow. -
The sole investment grade corporate new issue on Tuesday was a sub-benchmark seven year deal as weak secondary markets finally pulled the handbrake on new issuance. Some recent deals had struggled to tighten from initial price thoughts and issuers paused to take stock.
-
The IPO of Elkem, the Norwegian silicon producer and supplier being floated by ChemChina, priced on Wednesday at Nkr29 ($6.74) a share, the bottom of the expected range.
-
Barclays and Nordea will lead the financing of what is expected to be one of Europe's largest public to private takeovers this year, the acquisition of telecoms company TDC by DKT, a peer owned by a consortium of investors.
-
Books closed on the IPO of Siemens Healthineers, the healthcare technology division of Siemens, on Thursday lunchtime, with the base deal valued at €3.65bn and the company at €28bn.
-
Elkem, the Norwegian silicon producer and supplier being floated by ChemChina, has had a good start to bookbuilding after launching its Nkr7.7bn (€805m) flotation on the Oslo Børs on Monday.
-
-
The European Investment Bank printed a €5bn 10 year benchmark on Wednesday — the second largest deal of the year from a non-sovereign SSA issuer — dispelling any lingering concerns over the market’s reaction to the Italian election result.
-
Technopolis, the Finnish office space company, has signed a €518m multi-tranche loan, swapping most of its bilateral bank debt lines for syndicated funding.
-
The IPO of Siemens Healthineers was covered on day one of its bookbuild on Tuesday after its parent, Siemens, set a price range designed to please potential investors in the IPO of its medical technology division.
-
Kommunekredit has printed a €1bn five year note — but two more SSA borrowers are lining up further out in the curve.
-
Siemens has chosen to set a price range designed to please investors on the IPO of its medical technology division Siemens Healthineers, rather than seeking an aggressive valuation.
